AU2011342904B2 - Cell culture medium - Google Patents

Cell culture medium Download PDF

Info

Publication number
AU2011342904B2
AU2011342904B2 AU2011342904A AU2011342904A AU2011342904B2 AU 2011342904 B2 AU2011342904 B2 AU 2011342904B2 AU 2011342904 A AU2011342904 A AU 2011342904A AU 2011342904 A AU2011342904 A AU 2011342904A AU 2011342904 B2 AU2011342904 B2 AU 2011342904B2
Authority
AU
Australia
Prior art keywords
laminin
cells
cell culture
cell
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011342904A
Other languages
English (en)
Other versions
AU2011342904A1 (en
Inventor
Sergey Rodin
Karl Tryggvason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolamina AB
Original Assignee
Biolamina AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolamina AB filed Critical Biolamina AB
Publication of AU2011342904A1 publication Critical patent/AU2011342904A1/en
Application granted granted Critical
Publication of AU2011342904B2 publication Critical patent/AU2011342904B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011342904A 2010-12-17 2011-12-16 Cell culture medium Active AU2011342904B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201061424273P 2010-12-17 2010-12-17
US61/424,273 2010-12-17
US201161488353P 2011-05-20 2011-05-20
US61/488,353 2011-05-20
US201161533063P 2011-09-09 2011-09-09
US61/533,063 2011-09-09
US201161537940P 2011-09-22 2011-09-22
US61/537,940 2011-09-22
US201161565380P 2011-11-30 2011-11-30
US61/565,380 2011-11-30
US201161565849P 2011-12-01 2011-12-01
US61/565,849 2011-12-01
PCT/IB2011/003265 WO2012080844A1 (en) 2010-12-17 2011-12-16 Cell culture medium

Publications (2)

Publication Number Publication Date
AU2011342904A1 AU2011342904A1 (en) 2013-08-08
AU2011342904B2 true AU2011342904B2 (en) 2016-05-12

Family

ID=45755415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011342904A Active AU2011342904B2 (en) 2010-12-17 2011-12-16 Cell culture medium

Country Status (12)

Country Link
US (2) US8415156B2 (enExample)
EP (2) EP2651974B1 (enExample)
JP (2) JP5990531B2 (enExample)
KR (3) KR101921350B1 (enExample)
CN (2) CN103384679B (enExample)
AU (1) AU2011342904B2 (enExample)
BR (2) BR112013017629A2 (enExample)
CA (2) CA2826252C (enExample)
IL (2) IL226971B (enExample)
MX (2) MX345861B (enExample)
SG (3) SG191216A1 (enExample)
WO (2) WO2012080842A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US8415156B2 (en) * 2010-12-17 2013-04-09 Biolamina Ab Recombinant laminin-521
KR102048464B1 (ko) * 2011-09-22 2019-11-25 칼 트리그베이슨 라미닌 및 카데린를 포함하는 세포 배양 기질
WO2013080051A2 (en) 2011-11-30 2013-06-06 Biolamina Ab Methods of enhancing genetic diagnosis
DK2838992T3 (en) 2012-04-20 2018-02-05 Biolamina Ab Maintaining differentiated cells with laminins
US20130330825A1 (en) * 2012-06-07 2013-12-12 City Of Hope Attachment substrates for directed differentiation of human embryonic stem cells in culture
WO2014037807A2 (en) * 2012-09-07 2014-03-13 Biolamina Ab Stem cell bank
EP2925856B1 (en) 2012-12-03 2018-03-07 Biolamina AB Methods of producing rpe cells
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
ES2742444T3 (es) * 2013-07-02 2020-02-14 Nat Univ Singapore Diferenciación de células madre pluripotentes y células progenitoras cardíacas en fibras de cardiomiocito estriadas usando laminianas LN-15, LN-521 y LN-221
SG11201508796SA (en) * 2013-11-01 2015-11-27 Bbhc Co Ltd Method for producing induced pluripotent stem cell from mesenchymal stem cell and induced pluripotent stem cell produced by the method
RU2704984C1 (ru) 2013-11-27 2019-11-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Применение ламинина в культуре клеток эндотелия роговицы
CN113559246A (zh) 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
WO2016067629A1 (ja) * 2014-10-31 2016-05-06 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
DK3059307T5 (da) * 2015-02-20 2022-08-29 Inst Nat Sante Rech Med Anvendelse af et laminin til differentiering af pluripotente celler i hepatocytcellelinier
US20190359939A1 (en) * 2015-08-23 2019-11-28 Diamyd Medical Ab New use
ES2896548T3 (es) * 2015-10-30 2022-02-24 Biolamina Ab Métodos de producción de hepatocitos
JP6605618B2 (ja) * 2015-11-10 2019-11-20 日機装株式会社 細胞支持複合体および細胞支持複合体の製造方法
US11920155B2 (en) 2016-03-30 2024-03-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
US20190211305A1 (en) * 2016-08-25 2019-07-11 Kyoto University Method for Culturing Pluripotent Stem Cells on Specific Laminin
CA3042562C (en) * 2016-11-16 2023-02-28 Cynata Therapeutics Limited Pluripotent stem cell assay
CN106591295B (zh) * 2016-12-31 2019-10-25 贵州北科生物科技有限公司 一种多功能干细胞培养方法及所用培养基
CN110914407A (zh) 2017-05-05 2020-03-24 新加坡国立大学 人角质形成细胞的培养方法
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
US11603518B2 (en) 2019-01-23 2023-03-14 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN111621473A (zh) * 2019-04-03 2020-09-04 成熙(上海)生物科技有限公司 一种新型人源脂肪干细胞制剂的制备方法
CN111617105A (zh) * 2019-04-03 2020-09-04 成熙(上海)生物科技有限公司 一种脂肪干细胞多细胞活性因子冻干粉的制备方法
WO2021233116A1 (zh) * 2020-05-21 2021-11-25 北京大学 多能干细胞的成分明确、无异源的培养系统
CN111569048B (zh) * 2020-05-22 2023-04-18 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 LamG5肽在制备修复睾丸中支持细胞损伤的药物中的应用
WO2025067551A1 (zh) * 2024-05-16 2025-04-03 北京百普赛斯生物科技股份有限公司 活性增强的改造型Laminin 521蛋白及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005252B1 (en) * 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
EP2457999B1 (en) 2002-12-16 2018-10-17 Technion Research & Development Foundation Ltd. Culture medium for pluripotent stem cells
ES2383813T3 (es) * 2004-09-08 2012-06-26 Wisconsin Alumni Research Foundation Método de cultivo y cultivo de células madre embrionarias
JP2006087396A (ja) 2004-09-27 2006-04-06 National Institute For Environmental Studies 細胞培養基質及びその製造方法
JP2009506785A (ja) * 2005-11-18 2009-02-19 イムジェン カンパニー リミテッド 胚芽幹細胞の未分化増殖を誘導するオカダ酸含有培地組成物
EP1994141B1 (en) * 2006-02-23 2017-11-15 ViaCyte, Inc. Compositions and methods useful for culturing differentiable cells
DK2137295T3 (en) 2007-01-04 2018-06-25 Karl Tryggvason Use of a composition and method for enabling proliferation of pluripotent stem cells
US10829733B2 (en) 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
US8951799B2 (en) * 2007-01-04 2015-02-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent stem cells
WO2009006399A1 (en) 2007-07-01 2009-01-08 Lifescan Single pluripotent stem cell culture
ES2690554T3 (es) * 2008-03-17 2018-11-21 The Scripps Research Institute Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
US20110117645A1 (en) * 2008-03-31 2011-05-19 Oriental Yeast Co., Ltd. Method for proliferation of pluripotent stem cells
US20110318730A1 (en) 2008-07-07 2011-12-29 The Rockefeller University Micropatterned co-culture systems as infectious disease analysis platforms
JP5765714B2 (ja) 2009-05-29 2015-08-19 国立大学法人京都大学 人工多能性幹細胞の製造方法および培養方法
WO2010140698A1 (ja) * 2009-06-03 2010-12-09 国立大学法人東北大学 多能性幹細胞からの神経堤細胞群の分化誘導方法
CA2707296A1 (en) 2009-06-12 2010-12-12 Richard T. Scott, Jr. Method for relative quantitation of chromosomal dna copy number in a single or few cells
US8415156B2 (en) 2010-12-17 2013-04-09 Biolamina Ab Recombinant laminin-521

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NISHIUCHI et al:Matrix Biology. 2006;25(3):189-197 *
RODIN et al: "Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511" Nature Biotech; 2010;28(6):611 *
UNGER C. et al: "Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells." Human Reproduction. 2009;24(10):2567-2581 *
WANG et al: "Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells.", J. Biologica Chem. 2009;284(49):34054-34064 *
WANG G et al: "Noggin and bFGF cooperate to maintain the pluripotency of human embryonic stem cells in the absence of feeder layers", Biochemical Biophysical Res Comm. 2005;330(3):934-942 *

Also Published As

Publication number Publication date
SG191215A1 (en) 2013-07-31
JP2014501101A (ja) 2014-01-20
EP2651973B1 (en) 2016-08-31
JP2013545489A (ja) 2013-12-26
SG10201510405PA (en) 2016-01-28
CN103384680A (zh) 2013-11-06
MX2013006959A (es) 2013-12-06
MX2013006958A (es) 2013-12-16
MX345861B (es) 2017-02-20
BR112013017632A2 (pt) 2016-10-11
CA2826252C (en) 2018-12-04
SG191216A1 (en) 2013-07-31
CN103384679B (zh) 2015-08-26
CN103384680B (zh) 2015-08-26
MX343462B (es) 2016-11-07
IL270186B (en) 2020-08-31
EP2651974A1 (en) 2013-10-23
WO2012080844A1 (en) 2012-06-21
US10138292B2 (en) 2018-11-27
US8415156B2 (en) 2013-04-09
IL226971B (en) 2018-04-30
JP5990531B2 (ja) 2016-09-14
US20120156782A1 (en) 2012-06-21
WO2012080842A1 (en) 2012-06-21
KR20140016881A (ko) 2014-02-10
CN103384679A (zh) 2013-11-06
EP2651973A1 (en) 2013-10-23
JP6002675B2 (ja) 2016-10-05
KR101966033B1 (ko) 2019-04-04
KR20140012047A (ko) 2014-01-29
BR112013017629A2 (pt) 2017-04-18
CA2828794C (en) 2021-07-13
CA2826252A1 (en) 2012-06-21
US20120156254A1 (en) 2012-06-21
KR20190018024A (ko) 2019-02-20
KR101921350B1 (ko) 2018-11-22
EP2651974B1 (en) 2015-09-16
CA2828794A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
AU2011342904B2 (en) Cell culture medium
US12195757B2 (en) Methods of producing RPE cells
AU2017204108B2 (en) Cell culture medium
AU2011342904A1 (en) Cell culture medium
AU2016213884B2 (en) Recombinant laminin-511
AU2011342902B2 (en) Recombinant laminin-521
US9828630B2 (en) Methods of enhancing genetic diagnosis
AU2011342902A1 (en) Recombinant laminin-521

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)